We bring you the latest news from the healthcare about the health care in the United Kingdom.

maandag 1 oktober 2018

Nature Reviews Drug Discovery contents October 2018 Volume 17 Number 10 pp 689-757

If you are unable to see the message below, click here to view.
Nature Reviews Drug Discovery
TABLE OF CONTENTS

October 2018 Volume 17, Issue 10

Comment
News and Analysis
Research Highlights
Perspectives
Reviews
Erratum
 
Advertisement

BIOPHARMA DEALMAKERS
BIOPHARMA DEALMAKERSCompany Profiles and Partnering Opportunities

 

Comment

 
Genome editing to 're-write' wrongs   
Mary Ellen Perry, Kayla M. Valdes, Elizabeth Wilder, Christopher P. Austin & Philip J. Brooks

pp689 - 690 | doi:10.1038/nrd.2018.91
The NIH has launched the Somatic Cell Genome Editing (SCGE) programme to accelerate the development of safer and more effective genome-editing therapeutics.
Full Text | PDF
Collection: Genome Editing

 

News and Analysis

 
Microfluidics platform lowers barrier to drug combination screening   
Asher Mullard

pp691 - 692 | doi:10.1038/nrd.2018.161
Nanodroplets promise to reduce the equipment, cost and time constraints of high-throughput screening, if researchers can overcome long-standing hurdles.
Full Text | PDF


 
Malaria medicine box expands   
Asher Mullard

pp693 - 695 | doi:10.1038/nrd.2018.156
With the FDA's approval of GlaxoSmithKline's tafenoquine, global health experts will at last have access to a long-awaited new treatment for Plasmodium vivax recurrence. Much-needed novel treatments for the more common Plasmodium falciparum are in phase II trials.
Full Text | PDF


 
News in Brief
Industry advances landmark CRISPR candidate into the clinic   
Asher Mullard

p697 | doi:10.1038/nrd.2018.175
Full Text | PDF


 
Chi-Med scores key approval for 'discovered in China' cancer drug   
Asher Mullard

p697 | doi:10.1038/nrd.2018.176
Full Text | PDF


 
Painkilling anti-NGF antibodies stage phase III comeback   
Asher Mullard

p697 | doi:10.1038/nrd.2018.177
Full Text | PDF


 
Biobusiness Briefs
Trial watch: Burgeoning oncology pipeline raises questions about sustainability   
Jon Moser & Paul Verdin

pp698 - 699 | doi:10.1038/nrd.2018.165
Full Text | PDF


 
Market watch: Upcoming market catalysts in Q4 2018   
Stephanie Arthan

p699 | doi:10.1038/nrd.2018.162
Full Text | PDF


 
An Audience With
Ida Sim   
pp700 - 701 | doi:10.1038/nrd.2018.178
Ida Sim, Vivli co-founder and UCSF informatician, discusses the need for a neutral broker platform that can facilitate access to and analysis of industry and academic patient-level clinical trial data.
Full Text | PDF


 
From the analyst's couch
Trends driving clinical trials into large clinical care settings   
Kenneth Getz

pp703 - 704 | doi:10.1038/nrd.2018.111
This analysis highlights data indicating the limitations of traditional clinical trial processes, and discusses how moving clinical trials into large clinical care settings could help meet the growing demands for large volumes of sophisticated patient data.
Full Text | PDF
Collection: Cancer at Nature Research

 

Research Highlights

 
Neurodegenerative diseases: Ropin' in ALS
Megan Cully

p705 | doi:10.1038/nrd.2018.163
PDF


 
Ageing: Reversing muscle degeneration
Sarah Crunkhorn

p706 | doi:10.1038/nrd.2018.160
PDF


 
Cancer immunotherapy: When a CAR becomes a tank
M. Teresa Villanueva

p707 | doi:10.1038/nrd.2018.164
PDF


 
Genetic disorders: Bacterial therapeutic steps into the breach
Katie Kingwell

p708 | doi:10.1038/nrd.2018.166
PDF


 
In Brief
Metabolic disease: Preventing fat uptake
Sarah Crunkhorn

p708 | doi:10.1038/nrd.2018.170
PDF


 
Immunotherapy: Blocking T cell sequestration
Sarah Crunkhorn

p708 | doi:10.1038/nrd.2018.171
PDF


 
Cancer: Disrupting energy metabolism
Sarah Crunkhorn

p708 | doi:10.1038/nrd.2018.172
PDF


 
Obesity: Blocking ceramide formation
Sarah Crunkhorn

p708 | doi:10.1038/nrd.2018.173
PDF


 
Drug Discovery
EVENT
International Conference on Pharmaceutical Sciences and Drug Development (IPSDD 2018)
05.11.18
Prague, Czech Republic
More science events from

Perspectives

 
Opinion
Expanding the medicinal chemistry synthetic toolbox   
Jonas Boström, Dean G. Brown, Robert J. Young & György M. Keserü

pp709 - 727 | doi:10.1038/nrd.2018.116
Analysis of the role of synthetic organic chemistry in the identification of chemical starting points for drug discovery and subsequent optimization into candidate drugs indicates that a small number of reactions and commercially available building blocks dominate. This Perspective highlights opportunities for expanding the synthetic toolbox of medicinal chemists, potentially enabling the more effective exploration of therapeutically relevant chemical space.
Full Text | PDF


 

Reviews

 
Therapeutic approaches to Huntington disease: from the bench to the clinic   
Nicholas S. Caron, E. Ray Dorsey & Michael R. Hayden

pp729 - 750 | doi:10.1038/nrd.2018.133
New therapies, including RNA-based and gene therapies, are poised to change the therapeutic landscape for Huntington disease. In this article, Hayden and colleagues review the progress that has been made in the past 25 years in developing therapies for this disease and highlight the pitfalls and potential of future treatments.
Full Text | PDF


 
An RNA toolbox for cancer immunotherapy   
Fernando Pastor, Pedro Berraondo, Iñaki Etxeberria, Josh Frederick, Ugur Sahin et al.

pp751 - 767 | doi:10.1038/nrd.2018.132
In this Review, Pastor et al. provide an overview of RNA-based agents used in cancer immunotherapy — ranging from RNA vaccines encoding cancer neoantigens to interference RNAs and protein-binding RNA aptamers — providing insights into this emerging field.
Full Text | PDF
Collection: Cancer at Nature Research

 

Erratum

 
Gene therapy for neurological disorders: progress and prospects   
Benjamin E. Deverman, Bernard M. Ravina, Krystof S. Bankiewicz, Steven M. Paul & Dinah W. Y. Sah

p767 | doi:10.1038/nrd.2018.158
Full Text | PDF


 
Advertisement
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.

Springer Nature